Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.
The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.
“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” commented Christopher Viehbacher, President and CEO.
Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, versus the consensus of $14.92. The company expects revenue to decline by mid-single …